Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D reduced its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 14.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 170,264 shares of the biopharmaceutical company’s stock after selling 28,438 shares during the period. State of New Jersey Common Pension Fund D owned 0.06% of Amicus Therapeutics worth $1,818,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Janus Henderson Group PLC raised its holdings in shares of Amicus Therapeutics by 20.1% in the first quarter. Janus Henderson Group PLC now owns 13,814,514 shares of the biopharmaceutical company’s stock worth $162,713,000 after acquiring an additional 2,307,385 shares during the last quarter. William Blair Investment Management LLC lifted its holdings in Amicus Therapeutics by 12.8% in the 2nd quarter. William Blair Investment Management LLC now owns 13,003,363 shares of the biopharmaceutical company’s stock valued at $128,993,000 after purchasing an additional 1,477,084 shares in the last quarter. Fiera Capital Corp boosted its stake in shares of Amicus Therapeutics by 1.1% during the 2nd quarter. Fiera Capital Corp now owns 5,280,442 shares of the biopharmaceutical company’s stock worth $52,382,000 after purchasing an additional 58,113 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of Amicus Therapeutics by 14.3% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 3,020,536 shares of the biopharmaceutical company’s stock worth $29,964,000 after purchasing an additional 378,999 shares during the last quarter. Finally, Victory Capital Management Inc. grew its holdings in shares of Amicus Therapeutics by 17.9% during the second quarter. Victory Capital Management Inc. now owns 2,273,959 shares of the biopharmaceutical company’s stock worth $22,558,000 after buying an additional 345,117 shares in the last quarter.

Analysts Set New Price Targets

FOLD has been the topic of a number of analyst reports. StockNews.com upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday. Morgan Stanley decreased their price objective on Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Cantor Fitzgerald upped their target price on Amicus Therapeutics from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Jefferies Financial Group began coverage on Amicus Therapeutics in a research note on Friday, September 6th. They issued a “buy” rating and a $18.00 price target on the stock. Finally, Guggenheim upped their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $17.63.

Insider Activity

In other news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $10.60, for a total value of $79,500.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares in the company, valued at approximately $9,398,532.40. This trade represents a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders have sold 30,401 shares of company stock valued at $352,038. Company insiders own 2.20% of the company’s stock.

Amicus Therapeutics Stock Down 0.2 %

FOLD opened at $9.66 on Tuesday. The company has a market cap of $2.89 billion, a PE ratio of -28.41 and a beta of 0.68. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15. Amicus Therapeutics, Inc. has a 1 year low of $9.02 and a 1 year high of $14.57. The firm has a 50 day moving average price of $10.96 and a 200 day moving average price of $10.61.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.